Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 91

1.

MMP23B expression and protein levels in blood and urine are associated with bladder cancer.

Allione A, Pardini B, Viberti C, Giribaldi G, Turini S, Di Gaetano C, Guarrera S, Cordero F, Oderda M, Allasia M, Gontero P, Sacerdote C, Vineis P, Matullo G.

Carcinogenesis. 2018 Jul 20. doi: 10.1093/carcin/bgy098. [Epub ahead of print]

PMID:
30052775
2.

MicroRNAs as markers of progression in cervical cancer: a systematic review.

Pardini B, De Maria D, Francavilla A, Di Gaetano C, Ronco G, Naccarati A.

BMC Cancer. 2018 Jun 27;18(1):696. doi: 10.1186/s12885-018-4590-4.

3.

Coding variants in NOD-like receptors: An association study on risk and survival of colorectal cancer.

Huhn S, da Silva Filho MI, Sanmuganantham T, Pichulik T, Catalano C, Pardini B, Naccarati A, Polakova-Vymetálkova V, Jiraskova K, Vodickova L, Vodicka P, Löffler MW, Courth L, Wehkamp J, Din FVN, Timofeeva M, Farrington SM, Jansen L, Hemminki K, Chang-Claude J, Brenner H, Hoffmeister M, Dunlop MG, Weber ANR, Försti A.

PLoS One. 2018 Jun 21;13(6):e0199350. doi: 10.1371/journal.pone.0199350. eCollection 2018.

4.

microRNA profiles in urine by next-generation sequencing can stratify bladder cancer subtypes.

Pardini B, Cordero F, Naccarati A, Viberti C, Birolo G, Oderda M, Di Gaetano C, Arigoni M, Martina F, Calogero RA, Sacerdote C, Gontero P, Vineis P, Matullo G.

Oncotarget. 2018 Apr 17;9(29):20658-20669. doi: 10.18632/oncotarget.25057. eCollection 2018 Apr 17.

5.

DNA methylation profiling of asbestos-treated MeT5A cell line reveals novel pathways implicated in asbestos response.

Casalone E, Allione A, Viberti C, Pardini B, Guarrera S, Betti M, Dianzani I, Aldieri E, Matullo G.

Arch Toxicol. 2018 May;92(5):1785-1795. doi: 10.1007/s00204-018-2179-y. Epub 2018 Mar 9.

PMID:
29523930
6.

The prognostic value of basal DNA damage level in peripheral blood lymphocytes of patients affected by bladder cancer.

Allione A, Pardini B, Viberti C, Oderda M, Allasia M, Gontero P, Vineis P, Sacerdote C, Matullo G.

Urol Oncol. 2018 May;36(5):241.e15-241.e23. doi: 10.1016/j.urolonc.2018.01.006. Epub 2018 Feb 14.

PMID:
29426697
7.

Small non-coding RNA profiling in human biofluids and surrogate tissues from healthy individuals: description of the diverse and most represented species.

Ferrero G, Cordero F, Tarallo S, Arigoni M, Riccardo F, Gallo G, Ronco G, Allasia M, Kulkarni N, Matullo G, Vineis P, Calogero RA, Pardini B, Naccarati A.

Oncotarget. 2017 Dec 14;9(3):3097-3111. doi: 10.18632/oncotarget.23203. eCollection 2018 Jan 9.

8.

MicroRNA-binding site polymorphisms in genes involved in colorectal cancer etiopathogenesis and their impact on disease prognosis.

Schneiderova M, Naccarati A, Pardini B, Rosa F, Gaetano CD, Jiraskova K, Opattova A, Levy M, Veskrna K, Veskrnova V, Buchler T, Landi S, Vodicka P, Vymetalkova V.

Mutagenesis. 2017 Oct 17;32(5):533-542. doi: 10.1093/mutage/gex026.

PMID:
29048575
9.

Identification of plasma microRNAs as new potential biomarkers with high diagnostic power in human cutaneous melanoma.

Fogli S, Polini B, Carpi S, Pardini B, Naccarati A, Dubbini N, Lanza M, Breschi MC, Romanini A, Nieri P.

Tumour Biol. 2017 May;39(5):1010428317701646. doi: 10.1177/1010428317701646.

PMID:
28466785
10.

Increased micronucleus frequency in peripheral blood lymphocytes predicts the risk of bladder cancer.

Pardini B, Viberti C, Naccarati A, Allione A, Oderda M, Critelli R, Preto M, Zijno A, Cucchiarale G, Gontero P, Vineis P, Sacerdote C, Matullo G.

Br J Cancer. 2017 Jan 17;116(2):202-210. doi: 10.1038/bjc.2016.411. Epub 2016 Dec 13.

11.

Polymorphisms in microRNA binding sites of mucin genes as predictors of clinical outcome in colorectal cancer patients.

Vymetalkova V, Pardini B, Rosa F, Jiraskova K, Di Gaetano C, Bendova P, Levy M, Veskrnova V, Buchler T, Vodickova L, Naccarati A, Vodicka P.

Carcinogenesis. 2017 Jan;38(1):28-39. doi: 10.1093/carcin/bgw114. Epub 2016 Nov 1.

PMID:
27803053
12.

Polymorphisms in Non-coding RNA Genes and Their Targets Sites as Risk Factors of Sporadic Colorectal Cancer.

Vodicka P, Pardini B, Vymetalkova V, Naccarati A.

Adv Exp Med Biol. 2016;937:123-49. doi: 10.1007/978-3-319-42059-2_7. Review.

PMID:
27573898
13.

Epigenome-wide analysis of DNA methylation reveals a rectal cancer-specific epigenomic signature.

Vymetalkova V, Vodicka P, Pardini B, Rosa F, Levy M, Schneiderova M, Liska V, Vodickova L, Nilsson TK, Farkas SA.

Epigenomics. 2016 Sep;8(9):1193-207. doi: 10.2217/epi-2016-0044. Epub 2016 Aug 16.

PMID:
27529132
14.

H2AX phosphorylation level in peripheral blood mononuclear cells as an event-free survival predictor for bladder cancer.

Turinetto V, Pardini B, Allione A, Fiorito G, Viberti C, Guarrera S, Russo A, Anglesio S, Ruo Redda MG, Casetta G, Cucchiarale G, Destefanis P, Oderda M, Gontero P, Rolle L, Frea B, Vineis P, Sacerdote C, Giachino C, Matullo G.

Mol Carcinog. 2016 Nov;55(11):1833-1842. doi: 10.1002/mc.22431. Epub 2015 Nov 19.

15.

Double-strand break repair and colorectal cancer: gene variants within 3' UTRs and microRNAs binding as modulators of cancer risk and clinical outcome.

Naccarati A, Rosa F, Vymetalkova V, Barone E, Jiraskova K, Di Gaetano C, Novotny J, Levy M, Vodickova L, Gemignani F, Buchler T, Landi S, Vodicka P, Pardini B.

Oncotarget. 2016 Apr 26;7(17):23156-69. doi: 10.18632/oncotarget.6804.

16.

MicroRNA expression profiling in bladder cancer: the challenge of next-generation sequencing in tissues and biofluids.

Matullo G, Naccarati A, Pardini B.

Int J Cancer. 2016 May 15;138(10):2334-45. doi: 10.1002/ijc.29895. Epub 2015 Nov 9. Review.

17.

Genotype and Haplotype Analyses of TP53 Gene in Breast Cancer Patients: Association with Risk and Clinical Outcomes.

Vymetalkova V, Soucek P, Kunicka T, Jiraskova K, Brynychova V, Pardini B, Novosadova V, Polivkova Z, Kubackova K, Kozevnikovova R, Ambrus M, Vodickova L, Naccarati A, Vodicka P.

PLoS One. 2015 Jul 30;10(7):e0134463. doi: 10.1371/journal.pone.0134463. eCollection 2015.

18.

Circulating miRNAs miR-34a and miR-150 associated with colorectal cancer progression.

Aherne ST, Madden SF, Hughes DJ, Pardini B, Naccarati A, Levy M, Vodicka P, Neary P, Dowling P, Clynes M.

BMC Cancer. 2015 Apr 30;15:329. doi: 10.1186/s12885-015-1327-5.

19.

Inherited variability in a master regulator polymorphism (rs4846126) associates with survival in 5-FU treated colorectal cancer patients.

Pardini B, Bermejo JL, Naccarati A, Di Gaetano C, Rosa F, Legrand C, Novotny J, Vodicka P, Kumar R.

Mutat Res. 2014 Aug-Sep;766-767:7-13. doi: 10.1016/j.mrfmmm.2014.05.007. Epub 2014 Jun 7.

PMID:
25847265
20.

Elevated levels of 14-3-3 proteins, serotonin, gamma enolase and pyruvate kinase identified in clinical samples from patients diagnosed with colorectal cancer.

Dowling P, Hughes DJ, Larkin AM, Meiller J, Henry M, Meleady P, Lynch V, Pardini B, Naccarati A, Levy M, Vodicka P, Neary P, Clynes M.

Clin Chim Acta. 2015 Feb 20;441:133-41. doi: 10.1016/j.cca.2014.12.005. Epub 2014 Dec 23.

PMID:
25540887
21.

Polymorphisms in microRNA genes as predictors of clinical outcomes in colorectal cancer patients.

Pardini B, Rosa F, Naccarati A, Vymetalkova V, Ye Y, Wu X, di Gaetano C, Buchler T, Novotny J, Matullo G, Vodicka P.

Carcinogenesis. 2015 Jan;36(1):82-6. doi: 10.1093/carcin/bgu224. Epub 2014 Nov 3.

PMID:
25368035
22.

Single nucleotide polymorphisms within interferon signaling pathway genes are associated with colorectal cancer susceptibility and survival.

Lu S, Pardini B, Cheng B, Naccarati A, Huhn S, Vymetalkova V, Vodickova L, Buchler T, Hemminki K, Vodicka P, Försti A.

PLoS One. 2014 Oct 28;9(10):e111061. doi: 10.1371/journal.pone.0111061. eCollection 2014.

23.

Shorter leukocyte telomere length is independently associated with poor survival in patients with bladder cancer.

Russo A, Modica F, Guarrera S, Fiorito G, Pardini B, Viberti C, Allione A, Critelli R, Bosio A, Casetta G, Cucchiarale G, Destefanis P, Gontero P, Rolle L, Zitella A, Fontana D, Frea B, Vineis P, Sacerdote C, Matullo G.

Cancer Epidemiol Biomarkers Prev. 2014 Nov;23(11):2439-46. doi: 10.1158/1055-9965.EPI-14-0228. Epub 2014 Sep 18.

24.

MicroRNA expression in relation to different dietary habits: a comparison in stool and plasma samples.

Tarallo S, Pardini B, Mancuso G, Rosa F, Di Gaetano C, Rosina F, Vineis P, Naccarati A.

Mutagenesis. 2014 Sep;29(5):385-91. doi: 10.1093/mutage/geu028.

PMID:
25150024
25.

Variations in mismatch repair genes and colorectal cancer risk and clinical outcome.

Vymetalkova V, Pardini B, Rosa F, Di Gaetano C, Novotny J, Levy M, Buchler T, Slyskova J, Vodickova L, Naccarati A, Vodicka P.

Mutagenesis. 2014 Jul;29(4):259-65. doi: 10.1093/mutage/geu014. Epub 2014 Apr 22.

PMID:
24755277
26.

Colorectal cancer risk and patients' survival: influence of polymorphisms in genes somatically mutated in colorectal tumors.

Huhn S, Bevier M, Pardini B, Naccarati A, Vodickova L, Novotny J, Vodicka P, Hemminki K, Försti A.

Cancer Causes Control. 2014 Jun;25(6):759-69. doi: 10.1007/s10552-014-0379-1. Epub 2014 Apr 5.

PMID:
24706189
27.

Sardinians genetic background explained by runs of homozygosity and genomic regions under positive selection.

Di Gaetano C, Fiorito G, Ortu MF, Rosa F, Guarrera S, Pardini B, Cusi D, Frau F, Barlassina C, Troffa C, Argiolas G, Zaninello R, Fresu G, Glorioso N, Piazza A, Matullo G.

PLoS One. 2014 Mar 20;9(3):e91237. doi: 10.1371/journal.pone.0091237. eCollection 2014.

28.

Post-treatment recovery of suboptimal DNA repair capacity and gene expression levels in colorectal cancer patients.

Slyskova J, Cordero F, Pardini B, Korenkova V, Vymetalkova V, Bielik L, Vodickova L, Pitule P, Liska V, Matejka VM, Levy M, Buchler T, Kubista M, Naccarati A, Vodicka P.

Mol Carcinog. 2015 Sep;54(9):769-78. doi: 10.1002/mc.22141. Epub 2014 Mar 3.

29.

Molecular characteristics of mismatch repair genes in sporadic colorectal tumors in Czech patients.

Vymetalkova VP, Slyskova J, Korenkova V, Bielik L, Langerova L, Prochazka P, Rejhova A, Schwarzova L, Pardini B, Naccarati A, Vodicka P.

BMC Med Genet. 2014 Jan 31;15:17. doi: 10.1186/1471-2350-15-17.

30.

Association between CASP8 -652 6N del polymorphism (rs3834129) and colorectal cancer risk: results from a multi-centric study.

Pardini B, Verderio P, Pizzamiglio S, Nici C, Maiorana MV, Naccarati A, Vodickova L, Vymetalkova V, Veneroni S, Daidone MG, Ravagnani F, Bianchi T, Bujanda L, Carracedo A, Castells A, Ruiz-Ponte C, Morreau H, Howarth K, Jones A, Castellví-Bel S, Li L, Tomlinson I, Van Wezel T, Vodicka P, Radice P, Peterlongo P; EPICOLON Consortium.

PLoS One. 2014 Jan 21;9(1):e85538. doi: 10.1371/journal.pone.0085538. eCollection 2014. Erratum in: PLoS One. 2014;9(3):e91310.

31.

Meta-analysis of mismatch repair polymorphisms within the cogent consortium for colorectal cancer susceptibility.

Picelli S, Lorenzo Bermejo J, Chang-Claude J, Hoffmeister M, Fernández-Rozadilla C, Carracedo A, Castells A, Castellví-Bel S; Memebers of EPICOLON Consortium-Gastrointestinal Oncology Group of the Spanish Gastroenterological Association, Naccarati A, Pardini B, Vodickova L, Müller H, Talseth-Palmer BA, Stibbard G, Peterlongo P, Nici C, Veneroni S, Li L, Casey G, Tenesa A, Farrington SM, Tomlinson I, Moreno V, van Wezel T, Wijnen J, Dunlop M, Radice P, Scott RJ, Vodicka P, Ruiz-Ponte C, Brenner H, Buch S, Völzke H, Hampe J, Schafmayer C, Lindblom A.

PLoS One. 2013 Sep 6;8(9):e72091. doi: 10.1371/journal.pone.0072091. eCollection 2013.

32.

Variation within 3'-UTRs of base excision repair genes and response to therapy in colorectal cancer patients: A potential modulation of microRNAs binding.

Pardini B, Rosa F, Barone E, Di Gaetano C, Slyskova J, Novotny J, Levy M, Garritano S, Vodickova L, Buchler T, Gemignani F, Landi S, Vodicka P, Naccarati A.

Clin Cancer Res. 2013 Nov 1;19(21):6044-56. doi: 10.1158/1078-0432.CCR-13-0314. Epub 2013 Sep 13.

33.

Effect of blood storage conditions on DNA repair capacity measurements in peripheral blood mononuclear cells.

Allione A, Porcedda P, Russo A, Ricceri F, Simonelli V, Minoprio A, Guarrera S, Pardini B, Mazzei F, Dogliotti E, Giachino C, Matullo G.

Mutat Res. 2013 Sep;749(1-2):73-9. doi: 10.1016/j.mrfmmm.2013.05.001. Epub 2013 May 30.

34.

Genetic variants in C-type lectin genes are associated with colorectal cancer susceptibility and clinical outcome.

Lu S, Bevier M, Huhn S, Sainz J, Lascorz J, Pardini B, Naccarati A, Vodickova L, Novotny J, Hemminki K, Vodicka P, Försti A.

Int J Cancer. 2013 Nov 15;133(10):2325-33. doi: 10.1002/ijc.28251. Epub 2013 May 29.

35.

Polymorphisms in the XRCC1 gene modify survival of bladder cancer patients treated with chemotherapy.

Sacerdote C, Guarrera S, Ricceri F, Pardini B, Polidoro S, Allione A, Critelli R, Russo A, Andrew AS, Ye Y, Wu X, Kiemeney LA, Bosio A, Casetta G, Cucchiarale G, Destefanis P, Gontero P, Rolle L, Zitella A, Fontana D, Vineis P, Matullo G.

Int J Cancer. 2013 Oct 15;133(8):2004-9. doi: 10.1002/ijc.28186. Epub 2013 Apr 25.

36.

Shared ancestral susceptibility to colorectal cancer and other nutrition related diseases.

Huhn S, Bevier M, Rudolph A, Pardini B, Naccarati A, Hein R, Hoffmeister M, Vodickova L, Novotny J, Brenner H, Chang-Claude J, Hemminki K, Vodicka P, Försti A.

BMC Med Genet. 2012 Oct 5;13:94. doi: 10.1186/1471-2350-13-94.

37.

Differences in nucleotide excision repair capacity between newly diagnosed colorectal cancer patients and healthy controls.

Slyskova J, Naccarati A, Pardini B, Polakova V, Vodickova L, Smerhovsky Z, Levy M, Lipska L, Liska V, Vodicka P.

Mutagenesis. 2012 Jul;27(4):519-22. No abstract available.

PMID:
22919704
38.

Restless legs syndrome in Czech patients with multiple sclerosis: an epidemiological and genetic study.

Vávrová J, Kemlink D, Sonka K, Havrdová E, Horáková D, Pardini B, Müller-Myhsok B, Winkelmann J.

Sleep Med. 2012 Aug;13(7):848-51. doi: 10.1016/j.sleep.2012.03.012. Epub 2012 May 19.

PMID:
22609020
39.

Polymorphisms in miRNA-binding sites of nucleotide excision repair genes and colorectal cancer risk.

Naccarati A, Pardini B, Stefano L, Landi D, Slyskova J, Novotny J, Levy M, Polakova V, Lipska L, Vodicka P.

Carcinogenesis. 2012 Jul;33(7):1346-51. doi: 10.1093/carcin/bgs172. Epub 2012 May 11.

PMID:
22581836
40.

A comprehensive investigation on common polymorphisms in the MDR1/ABCB1 transporter gene and susceptibility to colorectal cancer.

Campa D, Sainz J, Pardini B, Vodickova L, Naccarati A, Rudolph A, Novotny J, Försti A, Buch S, von Schönfels W, Schafmayer C, Völzke H, Hoffmeister M, Frank B, Barale R, Hemminki K, Hampe J, Chang-Claude J, Brenner H, Vodicka P, Canzian F.

PLoS One. 2012;7(3):e32784. doi: 10.1371/journal.pone.0032784. Epub 2012 Mar 2.

41.

Differences in nucleotide excision repair capacity between newly diagnosed colorectal cancer patients and healthy controls.

Slyskova J, Naccarati A, Pardini B, Polakova V, Vodickova L, Smerhovsky Z, Levy M, Lipska L, Liska V, Vodicka P.

Mutagenesis. 2012 Mar;27(2):225-32. doi: 10.1093/mutage/ger088. Erratum in: Mutagenesis. 2012 Jul;27(4):519-22.

PMID:
22294771
42.

Mutations and polymorphisms in TP53 gene--an overview on the role in colorectal cancer.

Naccarati A, Polakova V, Pardini B, Vodickova L, Hemminki K, Kumar R, Vodicka P.

Mutagenesis. 2012 Mar;27(2):211-8. doi: 10.1093/mutage/ger067. Review.

PMID:
22294769
43.

Ancestral susceptibility to colorectal cancer.

Huhn S, Pardini B, Naccarati A, Vodicka P, Hemminki K, Försti A.

Mutagenesis. 2012 Mar;27(2):197-204. doi: 10.1093/mutage/ger061.

PMID:
22294767
44.

Gene expression variations: potentialities of master regulator polymorphisms in colorectal cancer risk.

Pardini B, Naccarati A, Vodicka P, Kumar R.

Mutagenesis. 2012 Mar;27(2):161-7. doi: 10.1093/mutage/ger057. Review.

PMID:
22294763
45.

Identification of candidate genes carrying polymorphisms associated with the risk of colorectal cancer by analyzing the colorectal mutome and microRNAome.

Landi D, Gemignani F, Pardini B, Naccarati A, Garritano S, Vodicka P, Vodickova L, Canzian F, Novotny J, Barale R, Landi S.

Cancer. 2012 Oct 1;118(19):4670-80. doi: 10.1002/cncr.27435. Epub 2012 Jan 26.

46.

Association of serum bilirubin and promoter variations in HMOX1 and UGT1A1 genes with sporadic colorectal cancer.

Jirásková A, Novotný J, Novotný L, Vodicka P, Pardini B, Naccarati A, Schwertner HA, Hubácek JA, Puncochárová L, Šmerhovský Z, Vítek L.

Int J Cancer. 2012 Oct 1;131(7):1549-55. doi: 10.1002/ijc.27412. Epub 2012 Feb 18.

47.

Association between TAS2R38 gene polymorphisms and colorectal cancer risk: a case-control study in two independent populations of Caucasian origin.

Carrai M, Steinke V, Vodicka P, Pardini B, Rahner N, Holinski-Feder E, Morak M, Schackert HK, Görgens H, Stemmler S, Betz B, Kloor M, Engel C, Büttner R, Naccarati A, Vodickova L, Novotny J, Stein A, Hemminki K, Propping P, Försti A, Canzian F, Barale R, Campa D.

PLoS One. 2011;6(6):e20464. doi: 10.1371/journal.pone.0020464. Epub 2011 Jun 2.

48.

Polymorphisms in CTNNBL1 in relation to colorectal cancer with evolutionary implications.

Huhn S, Ingelfinger D, Bermejo JL, Bevier M, Pardini B, Naccarati A, Steinke V, Rahner N, Holinski-Feder E, Morak M, Schackert HK, Görgens H, Pox CP, Goecke T, Kloor M, Loeffler M, Büttner R, Vodickova L, Novotny J, Demir K, Cruciat CM, Renneberg R, Huber W, Niehrs C, Boutros M, Propping P, Vodièka P, Hemminki K, Försti A.

Int J Mol Epidemiol Genet. 2011 Jan 1;2(1):36-50. Epub 2010 Nov 25.

49.

DNA damage and nucleotide excision repair capacity in healthy individuals.

Slyskova J, Naccarati A, Polakova V, Pardini B, Vodickova L, Stetina R, Schmuczerova J, Smerhovsky Z, Lipska L, Vodicka P.

Environ Mol Mutagen. 2011 Aug;52(7):511-7. doi: 10.1002/em.20650. Epub 2011 Apr 25.

PMID:
21520291
50.

MTHFR and MTRR genotype and haplotype analysis and colorectal cancer susceptibility in a case-control study from the Czech Republic.

Pardini B, Kumar R, Naccarati A, Prasad RB, Forsti A, Polakova V, Vodickova L, Novotny J, Hemminki K, Vodicka P.

Mutat Res. 2011 Mar 18;721(1):74-80. doi: 10.1016/j.mrgentox.2010.12.008. Epub 2011 Jan 4.

PMID:
21211571

Supplemental Content

Loading ...
Support Center